Our data suggest that targeting cholesterol synthesis and/or mTOR/Akt signaling may hold promise for ameliorating hypercapnia-induced immunosuppression and improving resistance to viral infection in patients with advanced lung disease and hypercapnia. Here, AKT1 is linked to lung disorder.